Unpowered exoskeletons with springs in parallel to human plantar flexor muscle-tendons can reduce the 27 metabolic cost of walking. We used ultrasound imaging to look 'under the skin' and measure how 28 exoskeleton stiffness alters soleus muscle contractile dynamics and shapes the user's metabolic rate 29 during walking. Eleven participants (4F, 7M; age: 27.7 ± 3.3 years) walked on a treadmill at 1.25 m s -1 30 and 0% grade with elastic ankle exoskeletons (rotational stiffness: 0-250 Nm rad -1 ) in one training and 31 two testing days. Metabolic savings were maximized (4.2%) at a stiffness of 50 Nm rad -1 . As 32 exoskeleton stiffness increased, the soleus muscle operated at longer lengths and improved economy 33 (force/activation) during early stance, but this benefit was offset by faster shortening velocity and poorer 34 economy in late stance. Changes in soleus activation rate correlated with changes in users' metabolic 35 rate (p = 0.038, R 2 = 0.44), highlighting a crucial link between muscle neuromechanics and exoskeleton 36 performance; perhaps informing future 'muscle-in-the loop' exoskeleton controllers designed to steer 37 contractile dynamics toward more economical force production. 38 39 40 41 48
INTRODUCTION
The plantar flexors serve an essential role in human walking by providing more than 50% of the leg's 43 total positive mechanical energy 1 and up to 60% of the mechanical power output for redirecting the 44 body's center of mass during push-off 2 . The importance of the ankle plantar flexors in legged 45 locomotion is linked to their morphology. Muscle-tendons (MTs) with short pennate muscle fibers and 46 long compliant in-series tendons are well suited for economical locomotion because the elastic tendons 47 store and return of mechanical energy over each step [3] [4] [5] . During steady-state walking, the interaction of increasing exoskeleton stiffness does not continue to improve metabolic rate during walking. Although 74 increased exoskeleton stiffness reduces force requirements on the plantar flexors, the tuned MT 75 interaction may become disrupted and result in poorer muscle economy (force/activation) and increased 76 metabolic rate. This disruption of MT interaction which elicits less economical muscle dynamics is 77 predicted by models and simulations of hopping 27,28 , walking 29-31 and running 32 and has been 78 demonstrated experimentally in both human hopping 33 and in isolated animal muscle experiments that 79 use a biorobotic interface to simulate exoskeleton interaction dynamics 34 . During human hopping, an 80 exoskeleton providing stiffness in parallel to the ankle plantar flexors reduced muscle force and net 81 metabolic rate, but increased soleus muscle positive work due to greater fascicle excursions 33 . In a 82 follow-up modelling study using the same hopping dataset, ankle exoskeleton torque reduced soleus 83 fascicle operating lengths and increased fascicle velocities 27 , which both acted to limit the estimated 84 metabolic savings from using the device. Musculoskeletal simulations of walking with a unilateral 85 elastic exoskeleton have demonstrated that applying ankle exoskeleton torque to the ankle-joint reduces 86 muscle force requirements, which leads to decreased tendon stretch and increased fascicle strain 17 . This 87 trend is also supported by a recent study that used ultrasound imaging to track the junction between the 88 medial gastrocnemius and Achilles tendon during walking with a dynamic orthosis 35 Rather than relying on model-based estimates, we sought to use ultrasound imaging techniques to 94 directly examine whether increasing ankle exoskeleton stiffness disrupts plantar flexor muscle-tendon 95 dynamics during walking (Fig. 1) . To date, no study has linked in vivo measurements of muscle 96 dynamics to a user's net metabolic rate during walking with exoskeletons. We used B-mode ultrasound 97 imaging to measure soleus muscle fascicle contractile dynamics in vivo during exoskeleton assisted 98 walking across a range of ankle exoskeleton rotational stiffnesses (kexo = 0, 50, 100, 150, 250 Nm rad -1 ). 99 We predicted that stiffer ankle exoskeletons would disrupt the normally tuned catapult behavior of the 100 ankle plantar flexors. Specifically, we hypothesized that increasing exoskeleton stiffness would (1) 101 reduce soleus muscle fascicle force, (2) reduce soleus activation, (3) increase soleus fascicle length and 102 (4) shortening velocity, and (5) alter soleus force per unit activation (i.e., muscle economy or force 103 production capacity). Taken together, we posit that ankle exoskeleton assistance elicits a trade-off 104 between reduced soleus force on one hand and a shift to contractile conditions that are less economical 105 for force production on the other. We suggest that this balance explains the metabolic 'sweet-spot' at 106 intermediate elastic ankle exoskeletons stiffness during walking. 107 108 RESULTS 109 To highlight the effect of exoskeleton stiffness on biomechanics and walking economy, the results focus 110 on the effect of two exoskeleton stiffnesses with respect to the 0 Nm rad -1 (no assistance) condition. The 111 50 Nm rad -1 condition details what occurs with a stiffness that is low but results in the metabolic 112 minimum. 18% for 50 and 250 Nm rad -1 respectively (Fig. 3Ai ). There was no reduction in force rate of early 150 stance (0-40% stride) (ANOVA; p = 0.38) ( Fig. 3Aii ). The change in average force rate of stance was 151 primarily from the decrease in the average force rate of late stance (40-60% stride) (ANOVA; p < 152 0.0001) which, compared to 0 Nm rad -1 , was reduced by 14% and 29% for 50 and 250 Nm rad -1 153 respectively ( Fig. 3Aiii ).
155
Soleus average activation rate, as measured by surface electromyography (EMG), decreased with 156 increasing exoskeleton stiffness during early stance (ANOVA; p = 0.0023) ( Fig. 3B and Table 1 ). The 157 reduction in activation rate of early stance was 14% and 21% for the 50 and 250 Nm rad -1 condition 158 compared to 0 Nm rad -1 ( Fig. 3Bii ). There was no change in activation rate of late stance (ANOVA p = 159 0.8765) ( Fig. 3Biii ).
161
The peak length of the soleus MT decreased with increasing exoskeleton stiffness (ANOVA; p < 162 0.0001). Compared to 0 Nm rad -1 , MT peak length decreased from 308 ± 6.6 mm to 306 ± 6.9 mm in the 163 50 Nm rad -1 condition and to 301 ± 6.9 mm in the 250 Nm rad -1 condition (Supp Fig. 1C ). Table 1 ). Compared to fascicle length at 0 Nm rad -1 (38.3 ± 168 6 1.6 mm), fascicle length at the time of peak force increased by 2.9% and 11.4% in the 50 and 250 Nm 169 rad -1 conditions respectively ( Fig. 3Ci, 4A) ; likely shifting the respective fascicles toward their optimal 170 length (l0) on the F-L curve ( Fig. 4C ).
172
Soleus fascicles shortened faster during stance with increasing exoskeleton stiffness, and this was 173 reflected by increased fascicle velocity at the time of peak force (ANOVA; p = 0.0318) ( Fig. 3D , 4D, 174 Table 1 ). Compared to the fascicle velocity at the time of peak force for 0 Nm rad -1 (0.47 ± 2.6 mm s -1 ), 175 fascicle shortening velocity increased by 0.4 ± 1.2 mm s -1 and 3.7 ± 1.6 mm s -1 in the 50 and 250 Nm Exoskeletons affected the economy of soleus force production in a phase dependent manner during 186 stance; likely improving it during early stance and worsening it during late stance. Soleus muscle 187 economy increased in early stance (ANOVA; p = 0.0448) ( Fig. 4B ~39 mm, which is up to 11% shorter than soleus optimal lengths reported in previous studies 40 . A study 220 that mapped participants' soleus length changes during walking at self-selected speed (mean = 1.14 ms -221 1 ) onto their empirically determined F-L curves found that humans operate at a nearly constant fascicle 222 length of ~0.9 l0 over early stance 8 . Assuming those in our study also operated at ~0.9 l0, we estimate the 223 soleus optimal length of 43.6 mm (39.2 mm/0.9) for our participants. Analysis (S1) for detailed analysis). We found evidence that elastic ankle exoskeletons influence whole-252 body net metabolic rate ̇ primarily through their impact on soleus muscle activation rate ( Fig. 3B ) 253 during the stance phase of walking (Table 2 , Fig. 5 ). Our mechanistic framework (S1, Eqs. S1-S7) 254 revealed that elastic exoskeletons modified soleus activation rate not just by modulating force demand 255 (S1, Eqs. S3-S4; Fig. 3A The rate of soleus active muscle volume ( ) captures the changes in local muscle dynamics (e.g., 262 force, length, velocity, and ultimately activation) due to elastic ankle exoskeleton torque and can explain 263 a significant portion (~44%, ( Table 2) We acknowledge certain potential limitations. The sessions were split among a training day and two 313 testing days and there is the potential for day to day variability. Our goal was to balance the conditions 314 that could be studied with the fatigue of the individual. Because individuals were trained and healthy 315 young adults with no muscular or neurological issues, we thought the tradeoff acceptable. In our 316 analysis and interpretation of muscle fascicle dynamics, while we were able to measure the dynamics of 317 the muscle using ultrasound, certain measurements were simplified or calculated based on common 318 assumptions. We did not measure optimal fascicle length directly but estimated that the optimal fascicle 319 length is ~0.9*l0 8 . The Achilles Tendon moment arm is geometrically derived 69 rather than capturing the 320 full complexity 70,71 . Due to our inability to directly measure soleus force and power, we used joint Regarding the design and development of future exoskeletons, our results reaffirm that net power 339 transfer from an exoskeleton is not necessary to reduce net metabolic rate during locomotion, even for 340 young adults whose plantar flexor neuromechanics are near optimally tuned for economical force 341 production 21,31 . This is primarily because net mechanical work from a device is not necessary to reduce 342 the muscle activation rate of the user, a key factor driving metabolic savings from exoskeleton assistance 343 ( The muscle-level links that we established between device function and user performance may provide 358 guidance for achieving a more complete symbiosis between human and machine. Exoskeletons that can 359 directly and seamlessly target muscle dynamics may provide even greater locomotion performance 360 benefits than current devices, perhaps beyond improving walking economy. One approach, inspired in For each participant, we calculated an average stride for each of the 5 conditions by time normalizing 450 each stride between heel-strike and heel-strike of the subsequent stride. We then averaged multiple 451 strides (15.5 ± 1.1) together to obtain a single normalized stride for each condition. We calculated the left leg (SX230, Biometrics Ltd, Newport, UK). To obtain an EMG envelope, we high-pass filtered 463 at 20Hz the raw EMG data, rectified, and low-pass filtered at 10Hz (zero-phase 2 nd order Butterworth). 464 Integrated EMG (iEMG) was the time-integral of the EMG envelope averaged across each stride for a 465 condition. We then normalized amplitude of the EMG envelope and the iEMG for each muscle to the 466 peak amplitude for the muscle across all conditions for each participant. Then, we divided the iEMG by heel-strike of the subsequent stride. We averaged together a minimum of three normalized strides (6 ± 506 0.6 stride average) to obtain a single normalized stride for a given condition. Integrated and peak values 507 were calculated prior to inter-stride averaging. We calculated soleus muscle fascicle length at the time of 508 peak force with the intention of observing changes in fascicle length due to changes in MT stretch. For 509 each condition, we then averaged the length measured at peak force for at least three strides. Researchers 510 were not blinded to the conditions during processing, but conditions were processed in random order.
512
Finally, to evaluate the influence of force-length (F-L) and force-velocity (F-V) effects on the capacity 513 of the soleus muscle to produce force we computed its force per activation (N kg -1 ) (see S1, Eq. S7 for 514 details on this metric). To do this we divided the average muscle force rate by the average muscle 515 activation rate over the same distinct phases of the stride described previously for force and activation 516 measures (i.e., all of stance (0-60%), early stance (0-40%) and late stance (40-60%) of the stride). (Fexo = 0), the entirety of the ankle force (Fank) is directed through the biological structure (Fbio = Fank). With exoskeleton 798 assistance in parallel, a portion of the total ankle force is shunted to the exoskeleton resulting in a decrease in the biological 799 force requirements (Fbio = Fank -Fexo). As a result of decreased biological force and because the tendon is a passive element, 800
we expect the tendon strain to decrease by ∆T = ∆Fbio*(tendon stiffness). Finally, if length changes of the MT do not change 801 much, we expect the muscle fascicles to be longer when exoskeleton parallel assistance is applied. In this study, we tested 802 this hypothesis by using ultrasound to directly measure soleus fascicle length during walking with elastic ankle exoskeletons 803 over a broad range of stiffnesses. production. (A) (Top) Soleus fascicle length at peak fascicle force for each stiffness. (Bottom) Difference in soleus fascicle 831 length at peak force relative to the zero stiffness conditions. The two high stiffness conditions (orange and red) were 832 significantly longer than 0 Nm rad -1 (ANOVA *p < 0.0001; THSD # p < 0.0001). (B) Average muscle force per activation 833 (i.e., muscle economy) during early stance (0-40%) of the gait cycle. Muscle economy increased (*p<0.0448) with increased 834 exoskeleton stiffness as might be expected from improved operating point on the F-L curve during early stance. (C) Fascicle 835 operating length at peak force relative to estimated muscle force-length (F-L) curve with optimal length l0 = 43.6 mm and 836
inset of a narrowed scale. Data indicates a rightward shift of the F-L curve with increased exoskeleton stiffness and increased 837 force production capacity. (D) (Top) Soleus fascicle velocity at peak fascicle force for each stiffness (*p=0.032). (Bottom) 838
Difference in soleus fascicle velocity at peak force relative to the zero stiffness conditions. (E) Average muscle force per 839 activation during late stance (40-60%) of the gait cycle. Muscle economy decreased with increased exoskeleton stiffness as 840 might be expected from a shift in operating point on the F-V curve during late stance. The two high stiffness conditions 841 (orange and red) were significantly different than 0 Nm rad -1 (ANOVA *p = 0.0258; THSD ## p = 0.0351 & 0.0325). (F) 842
Fascicle operating point at peak force on estimated muscle force-velocity (F-V) curve assuming vmax of 262 mm s -1 . Shift in 843 muscle velocity to the right with increased stiffness shown in inset due to narrow range of shortening velocities near v = 0 844 mm s -1 . All bars graphs show mean ± SEM across N=10 participants. 845 against change in soleus activation rate (unitless s -1 ) with respect to no assistance (k = 0 Nm rad -1 ). Changes in soleus 847 activation rate were significantly correlated with changes in users' net metabolic rate (p = 0.038; R 2 = 0.44. 848 imposed waiting period between each testing session was 2-7 days to allow for learning and retention 89 and reduce fatigue. 855
Participants were trained in the first session on all stiffnesses at 1.25 m s -1 . During the second session, we recorded joint 856 mechanics, electromyography (EMG), and ultrasound data for 5 exoskeleton conditions (krot = 0, 50, 100, 150, 250 Nm rad -1 ). 857
In the third session, we recorded steady state metabolic cost for the same conditions. 858 859 860 Table 2 . The relationships between the change in net metabolic rate (W kg -1 ) (y) and changes in soleus muscle 877 neuromechanics (x) during walking with exoskeletons over a range of stiffness values, kexo. For each metric, Δ represents the 878 difference from the kexo=0 condition (i.e., the effect of increasing exoskeleton stiffness) with positive values indicating an 879 increase. We used a within-participant linear regression analysis to determine whether relationships were significant (p < 880 0.05), and for those that were, we report the line of best fit to the data and the R 2 value of the fit. Bold underline indicates a 881 significant relationship between the change in a given neuromechanical variable, x and the change in whole-body net 882 metabolic rate, y. 
